- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
AstraZeneca opens new manufacturing facility in Russia
20 October 2015 • Author: Victoria White
AstraZeneca has opened its new state-of-the-art manufacturing and packaging facility in Kaluga, Russia, dedicated to the local supply of innovative medicines.
AstraZeneca was one of the first multinational pharmaceutical companies to announce plans to invest in the construction of a dedicated manufacturing facility in Russia in 2011. Four years on, the Company has invested $224m in the development, which is the largest foreign investment in the construction of a new pharmaceutical facility in the country.
AstraZeneca now employs more than 1,400 people in Russia working across commercial, manufacturing, scientific and clinical research and enabling functions. Around 50 of AstraZeneca’s innovative medicines are licensed for sale in Russia.
Commenting from Russia on the opening of the Kaluga facility, Pascal Soriot, Chief Executive Officer, said, “Our new dedicated production facility will support our efforts to bring innovative medicines from our exciting pipeline to patients in Russia. This opening builds on our investments in clinical research and scientific collaborations in this important country and serves to reinforce our long term commitment to Russia.”
AstraZeneca’s new site to become fully operational in 2017
Commercial production will begin early next year and will focus on final-stage manufacturing, packaging and quality control. The site will become fully operational in 2017 and will produce around 40 million packs and 850 million tablets of some 30 innovative medicines every year. This represents more than 60% of AstraZeneca’s medicines marketed in Russia to treat diseases across the Company’s therapy areas.
The new facility adds to the expansion of AstraZeneca’s global manufacturing capabilities to support the company’s expanding portfolio of medicines and growing demand, following on from the planned biologics manufacturing investments in Sweden, the acquisition of a new site in Boulder, Colorado, US, and the expansion in Frederick, Maryland, US.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics